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Abstract
The liver performs critical physiological functions, including metabolizing and removing substances, such as toxins and drugs, from the bloodstream. Hepatotoxicity itself is intimately linked to abnormal hepatic transport and hepatotoxicity remains the primary reason drugs in development fail and approved drugs are withdrawn from the market. For this reason, we propose to analyze, across liver compartments, the transport kinetics of fluorescein-a fluorescent marker used as a proxy for drug moleculesusing intravital microscopy data. To resolve the transport kinetics quantitatively from fluorescence data, we account for the effect that different liver compartments (with different chemical properties) have on fluorescein's emission rate. To do so, we develop ordinary differential equation transport models from the data where the kinetics are related to the observable fluorescence levels by "measurement parameters" that vary across different liver compartments. On account of the steep non-linearities in the kinetics and stochasticity inherent to the model, we infer kinetic and measurement parameters by generalizing the method of parameter cascades. For this application, the method of parameter cascades ensures fast and precise parameter estimates from noisy time traces.
INTRODUCTION Physiological Context of Hepatotoxicity
Liver transport is a fundamental physiological process whose significance to human health has increased with the proliferation of pharmaceuticals and environmental toxins. [1] [2] [3] Since the liver is a primary venue for the clearance of xenobiotics, it is particularly susceptible to druginduced injury, in a process known as hepatotoxicity. [4] [5] [6] Drug hepatotoxicity is associated with inhibition of hepatic transport 7-9 through the inhibition of transporters. 10, 11 Drug effects on hepatic transporters are also a major cause of drug-drug interactions, compromising drug safety and complicating drug dosing. 12 Although hepatic side effects are a primary focus of preclinical drug evaluations, drug-induced liver injury affects an estimated million people each year globally, and is the most common cause for withdrawal of drugs from the market.
13,14
Typically, the effects of a drug on hepatic transport are first evaluated outside animal models such as in studies of vesicle preparations or cultured cells. 15 While these simplified systems yield accurate kinetic transport parameters, they also have key limitations: 1) they do not recapitulate the complexity of typical clinical situations, which may include one or more pathological conditions in an individual taking a combination of drugs; 16 and 2) they lack the pharmacokinetic processes that determine drug distributions, confounding prediction of in vivo drug effects from in vitro dose-response curves. 17, 18 In other words, they lack the full complexity of in vivo transport, a non-vectorial process mediated by the simultaneous activity of multiple transporters.
19,20
By contrast, laboratory animals, combined with the tools of intravital microscopy (IVM) data, 21 provide the necessary physiological context. 22 The failure to predict drug transport inside the liver from IVM data, however, highlights fundamental shortcomings in how we exploit the data. In principle, the data contains information on the mechanism of vectorial drug transport involving different transporters, often with overlapping specificities. Imaging methods also, simultaneously, are poised to provide spatial and temporal resolution on how drugs might impact liver transport from their point of uptake into hepatocytes, through secretion into the bile, with secretion back into the blood, or flow in the biliary tract.
23,24
Recently, some studies have used IVM 21, 25, 26 to monitor transport kinetics of sodium fluorescein 27, 28 and identify the effects of chronic kidney disease on organic anion transport.
29
While rich in structure, the IVM data also presents important challenges toward achieving a complete picture of fluorescein's transport kinetics as it evolves from the liver capillaries (sinusoids) into the cytosol of the hepatocytes (uptake) and then into the bile canaliculi (canalicular secretion), from which they are cleared into the bile. However, fluorescein's emission is deeply dependent on its local chemical environment. That is, the fluorescence signal from these probes is sensitive to environmental quenching 30, 31 and fluorescein itself may exist in multiple forms, e.g., glucuronidated form, 30 across liver compartments.
Thus, in this study, we combine experiments and theory to develop a quantitative method to analyze hepatic transport from fluorescence time measurements using IVM data. In particular, we model the kinetics of hepatic transport, in other words the kinetics of transport of fluorescent species, using a set of ordinary differential equations (ODEs). [32] [33] [34] [35] [36] [37] We treat the units of fluorescing species in a particular compartment and their kinetics between liver compartments as a hidden (latent) variables and introduce measurement parameters to describe the relationship between the absolute concentrations and fluorescence intensity in different observed regions. We calibrate our ODE model, i.e., infer kinetic and measurement parameters, from noisy fluorescence time traces obtained from IVM using the method of parameter cascades. 54 Using this method, ODE solutions are approximated using spline coefficients.
38

Mathematical Methods of ODE Parameter Estimation
These coefficients are estimated with penalized smoothing splines with a roughness penalty term.
MATERIALS AND METHODS
Experimental Methods
Here we used quantitative IVM data for transport in the liver of rats with 5/6th nephrectomy (5/6N) 55, 56 where hepatic drug transport is impacted by chronic kidney disease. 29, 56 This data was previously published and information on 5/6N rat models and IVM data collection is detailed in Refs. 29 and.
21
ODE Model and Parameter Estimation
We begin with a set of ODEs describing the evolution in time, t, of a species vector, x, of length m whose elements are units of fluorescence in a particular compartmenṫ
In particular, the species coincide with different chemical forms of fluorescein, i.e., modified by being glucuronidated, 30 and unmodified forms in each compartment. The vector θ contains parameters (kinetic rates describing transport parameters between liver compartments) whose values are a priori unknown. The vector, x itself is not directly observed.
Rather, we supplement the dynamical model above with the following measurement model 
where x is the approximation of the curve x in terms of our linear expansion. We use i to iterate over the m species in our model and call the expansion coefficients c ik nuisance parameters. The basis functions must themselves approximate the ODE solutions. We selected B-splines as these basis functions allow us to appropriately control solution smoothness across time as warranted by the data which serves as input. 41, 53 The number of basis functions must be large enough to adequately represent x 58 and the function x i must be learned by optimizing a global objective function that, at once, satisfies the ODE and adequately fits the noisy data. 59 We then iterate between two optimization routines until a pre-specified criterion for the global optimum is met. In the first optimization step, the nuisance parameters, c, are estimated using a smoothing ODE-penalized criterion, in a process known as inner optimization. Within the inner optimization, the structural parameters are kept fixed and the nuisance parameters are fitted to data by minimizing the following penalized sum of squares.
In the inner optimization, the regularization parameter, λ, controls the trade off between fitting the data and fidelity to the ODEs for each x i . Intuitively, for larger noise, as defined by Eq. (2), we need larger λ as the data themselves become less reliable.
In the outer optimization step, the structural parameters, θ , are updated by minimizing the following sum of squared errors between the data y i and our estimates x i
Here J out (θ |λ, y) is minimized with respect to θ by using the Newton-Raphson method.
The following pseudo-code (further detailed in Supplementary Information Appendix A) sketches this procedure. Estimate θ by minimizing J out (θ |y, λ) given by Eq. (5) if θ are changed (to within some preset precision), J in ( c |θ , λ) is reoptimized with respect to c then goto Inner optimization.
else θ = θ . close;
To be clear, we explicitly include measurement parameters among the structural parameters. The ability to incorporate measurement parameters constitutes an important gener-alization of the method of cascades to deal with noisy data that was previously suggested. 38 We highlight here that the method of cascades is an important, fast and general alternative to extended Kalman filters or other Kalman filter variants. [60] [61] [62] Kalman filters may solve similar problems to that above but may suffer in the case of pronounced non-linearities in the dynamics, i.e., Eq. (1). This is especially relevant to us here as we would like our method to hold for a broad range of non-linear dynamics.
63,64
In the Supplementary Information Appendix B, we describe in greater detail how confidence intervals of parameters estimates are determined. Briefly, here we mention that if the data are poor or data sets are too small for the number of parameters to be estimated, the global objective function may be flat around its maximum and unable to sharply discriminate between different parameter values (a problem known as "weak identifiability" 65, 66 ). By contrast, "structural unidentifiability" arises when model parameters are not independent and different parameter choices result in equally good fits. 
Method Validation
To test our method, we validate its performance on systems of increasing complexity using sets of simulated (i.e., synthetic) data, where the ground truth is known. 
with measurements
where θ = [k + , k − , α, β] being the unknown structural parameter vector. The mean of both 1 and 2 is zero and the variance of both is assumed known, i.e., the measurement noise assumed Gaussian is fixed in a pre-calibration step. To resolve structural unidentifiability (see the Supplementary Information Appendix B), we must specify either α or β. For concreteness, we presume that from other experiments, it is known that α = 0.5 and thus we are left with 3 unknown parameters.
The solutions to Eqs. (6) and (7) are plotted in We also tested the accuracy of our approach by adding white noise with different variances, namely 0.05, 0.1 and 0.2, to our simulated data. In Fig. (2) and Table (1), we show the results of our fitting and parameter estimation. dots are generated data points, the dash lines are theoretical curves, and the solid lines are the fits on our data. AU here stands for arbitrary units.
2-Generalized Two States System: We continue testing our approach by generalizing the previous example. That is, we have two de-coupled sets of ODEs for the dynamics whose outputs are coupled by measurement. That is, we have 
and
The above reflects, for example, two different fluorescent species (the primed and unprimed) hopping between two compartments (subscripted one and two). Measurements on both compartments reveal the total amount of fluorescent material in each compartment but does not discriminate between the primed and unprimed.
The structural parameter vector here is
To eliminate structural unidentifiability, using the procedure highlighted earlier, we specify α = 0.5 and α = 0.25. The solutions to Eqs. (8)- (10) We test the accuracy of our approach by considering white noise with different variances (0.05, 0.1 and 0.2) added to our simulated data. In Fig. (3) and Table ( 2) we show the results of our fitting and parameter estimation with and without noise.
3-FitzHugh-Nagumo Model : Finally, we tested our method with one of the best known models, developed by FitzHugh 70 and Nagumo et al. 71 to examine the behavior of spike potentials in the giant axon of squid neurons. While this model is dissimilar in structure to our hepatic transport model, the FitzHugh-Nagumo model, shown below, is often used as a benchmark in ODE parameter estimation problems
This system describes the mutual dependency between voltage across an axon membrane, In addition to the above, we supplement the dynamical model with a measurement model
Thus, the parameters to be determined are now θ = [a, b, c, α, β]. Identifiability demands 
RESULTS
Full Hepatic Transport Model
We now construct a model of hepatic transport. Transport in the liver consists of fluorescein transport between and through sinusoid blood vessels, into the hepatocytes and then into the canaliculi. 21 The data we have collected consists of fluorescence intensity from fluorescein in all three compartments.
To construct our model, we: 1) assume no direct transport between sinusoid and canaliculus; and 2) assume only three compartments (sinusoid, hepatocyte and canaliculus). In this case, we designate fluorescein species in the sinusoid, hepatocyte and canaliculus as S(t), H(t), and C(t) respectively. In full generality, we also consider back flow from the hepatocyte back into the sinusoid.
We treat fluorescein in each compartment as a different species with a different measurement parameter since each compartment presents variable quenchers species and concentrations (e.g., binding proteins reducig fluorescein net emission). 21 What is more, we consider two forms of fluorescein, both unmodified and glucuronidated as it is known that the majority of fluorescein is glucuronidated within 30 minutes of intravenous injection.
30
A schematic of the model is provided in Fig. (5) . In our model, the species vector, previously written as x in Eq. (1), includes the unit of measurement for unmodified and modified we have six species, glucuronidated and unmodified fluorescein in three compartments, we only have three measurements, namely the fluorescence intensity in each compartment. Based on the model schematic provided in Fig. (5) , after pre-specifying the input rate into the sinusoid thereby setting initial conditions, the dynamical model is given by
The measurement model is now
The parameters α, β, and γ and their primes are our measurement parameters for unmodified and glucuronidated fluorescein in each compartment. We note that, in this case, the measurement matrix H is no longer square or diagonal; at any given time, we have fewer measurements than number of species in our model.
Furthermore, just as we did with simulated data, we used the identifiability problem procedure (detailed in the Supplementary Information Appendix B) and, on this basis, pre- 
Study on Sham Control and 5/6N Rat Model of Chronic Kidney Disease
Here, we used IVM data from 5/6N rat models as these are often used as models for the study of chronic kidney disease. 73 To evaluate the functional outcomes of the 5/6N model on hepatic transport, we collected IVM data 29 in the liver of sham control operated rats The results for these studies are shown in Tables (4) and (5). Similar to previously published work, e.g., 29 our results also show a meaningful change in hepatic transport in 5/6N as compared to the sham control. Concretely, our analysis reveals that the 5/6N, when compared to the sham control operated rats, exhibited a decrease rate of hepatic uptake of fluorescein. Put differently, we anticipate differences in k S→H , k H→S , k S→H , and k H→S between these two cases, as hepatic transport is impaired in the 5/6N rat. To resolve model unidentifiability, we pre-specify k HT as well as the measurement parameters α and α in our model. We chose k HT and those two parameters as their values are the easiest to determine via physiological experiments [74] [75] [76] or via fluorescence lifetime imaging. 77 Our quantitative conclusions are insensitive to exact parameter estimates used initially for k HT , α and α . 
Effect of Taurolithocholate
In the previous subsection, we devised a control to assess the functional consequences of the 5/6N and recovered a change in transport rates from the sinusoid to the hepatocyte. Now, we look at different treatment controls using Taurolithocholate (TLC) treated rats.
29 TLC is a pharmaceutical agent that inhibits transport from the hepatocyte to the canaliculus and out from the canaliculus, so we expect these relevant rates to decrease.
TLC-induced cholestasis is a common experimental model for drug-induced cholestasis. [78] [79] [80] According to previous work, TLC impairs hepatic transport 81 and also significantly blocks hepatocyte uptake of sodium fluorescein. 80 Thus, by using TLC treated rat models, we could evaluate our method to see how well it works in estimating transport rates from the hepatocyte to the canaliculus and transport rates from canaliculus out.
The result of blocking hepatocyte uptake of sodium fluorescein using TLC treated rat on hepatocyte is shown in Fig. (6C) . The estimated ODE parameter values for this data set appear in Table ( 6) where we note the blocking effect TLC has on secretions to and from the canaliculus recovered by our model as measured by the small values for the rates k H→C and k C . Table 4 . In (B) we show results for a 5/6N rat model in which the kidneys were removed. The main difference between (A) and (B) is the change in the rate of hepatic uptake of fluorescein as quantified by the rates from the sinusoid to the hepatocyte between the sham control and 5/6N rats for both glucuronidated and unglucuronidated forms of fluorescein. More details on the rat model are provided in Ref.
29 In (C) we show example images collected from a rat treated by the agent TLC obtained after intravenous injection. The TLC highly reduces the rate of fluorescein uptake into the canaliculus. 
DISCUSSION AND CONCLUSIONS
Drug development is a long and costly endeavor; the average drug costs nearly a billion dollars and takes roughly 15 years to bring to market. 82, 83 Given these costs and timescales, it is critical to identify the efficacy and risks associated with a candidate drug early in the development process. Clearly improving the prediction of drug failures could substantially reduce development costs. one that we tailored to IVM experimental data on hepatic transport.
In the context of Biophysics, parameter inference methods have a comparatively long history. [88] [89] [90] [91] [92] [93] [94] [95] [96] The goal of parameter estimation is to find unknown parameters of the model that give the best fit to a set of experimental data. 97 While a number of methods tailored to learning parameters from ODEs exist, many of them require that the ODEs be numerically solved 39,40 which entails expensive computation and requires knowing the initial values of the ODE variables. However, efficient computational methods exist that do not require actually solving the ODEs numerically. [41] [42] [43] A drawback for many of these methods is that they do not take into account errors approximation when making parameter inferences, which causes the well-known bias problem. 44 On the other hand, we deal with these problems through parameter cascades by defining two nested levels of optimization in our adaptation. In the inner optimization loop, we estimated nuisance parameters (coefficients of basis function).
Then structural parameters are estimated in the outer optimization loop. 
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ODE Model and Parameter Estimation
We begin with a set of ODEs describing the evolution in time, t, of a species vector, x, of length m whose elements are units of fluorescence in a particular compartmenṫ x(t) = f(x, t|✓).
(
In particular, the species coincide with di↵erent chemical forms of fluorescein, i.e., modified by being glucuronidated, 30 and unmodified forms in each compartment. The vector ✓ contains parameters (kinetic rates describing transport parameters between liver compartments) whose values are a priori unknown. The vector, x itself is not directly observed.
Rather, we supplement the dynamical model above with the following measurement model y(t) = Hx(t) + ✏(t)
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Rather, we supplement the dynamical model above with the following measurement model y(t) = Hx(t) + ✏(t) Signal (AU)
